Development of minimally invasive cancer immunotherapy using anti-disialoganglioside GD2 antibody-producing mesenchymal stem cells for a neuroblastoma mouse model

Researchers engineered mesenchymal stem cells to produce anti-GD2 antibodies and demonstrated tumor homing with significant growth suppression in a neuroblastoma mouse model when combined with IL-2. This novel cellular immunotherapy approach increased natural killer cell infiltration and may offer a minimally invasive treatment strategy for high-risk pediatric neuroblastoma.